Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-141 · 1 trial · 1 indication
Cmax of ABBV-141 will be assessed.
Tmax of ABBV-141 will be assessed.
AUCt of ABBV-141 will be determined.
AUCinf of ABBV-141 will be assessed.
Terminal phase elimination rate constant (β) of ABBV-141 will be assessed.
Terminal phase elimination half-life (t1/2) of ABBV-141 will be assessed.
Dose normalized Cmax of ABBV-141 will be assessed.
Dose normalized AUC of ABBV-141 will be assessed.
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
| Arm | Type | Description |
|---|---|---|
| Part 1, ABBV-141 (Intravenous [IV]) | EXPERIMENTAL | Western participants will receive a single IV dose of ABBV-141. |
| Part 1, Placebo for ABBV-141 (IV) | PLACEBO_COMPARATOR | Western participants will receive a single IV dose of placebo for ABBV-141. |
| Part 1, ABBV-141 (subcutaneous [SC]) | EXPERIMENTAL | Western participants will receive a single SC dose of ABBV-141. |
| Part 1, Placebo for ABBV-141 (SC) | PLACEBO_COMPARATOR | Western participants will receive a single SC dose of placebo for ABBV-141. |
| Part 2, ABBV-141 (IV) | EXPERIMENTAL | Asian participants will receive a single IV dose of ABBV-141. |
| Part 2, Placebo for ABBV-141 (IV) | PLACEBO_COMPARATOR | Asian participants will receive a single IV dose of placebo for ABBV-141. |
| Part 2, ABBV-141 (SC) | EXPERIMENTAL | Asian participants will receive a single SC dose of ABBV-141. |
| Part 2, Placebo for ABBV-141 (SC) | PLACEBO_COMPARATOR | Asian participants will receive a single SC dose of placebo for ABBV-141. |
| Name | Type | Description |
|---|---|---|
| ABBV-141 | DRUG | Infusion; intravenous (IV) |
| Placebo for ABBV-141 | DRUG | Infusion; IV |
Inclusion Criteria: * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG). * Body Mass Index (BMI) is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal. For Part 2 onl...
ABBV-141 is an investigational small molecule drug developed by AbbVie Inc. It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific disease or condition it is intended to treat has not been disclosed.
ABBV-141 is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker symbol ABBV. AbbVie is the sponsor of the clinical trial evaluating the drug.
ABBV-141 is in Phase 1 clinical development. One Phase 1 trial has been completed. The drug is investigational and has not been approved by the FDA for any indication.
ABBV-141 has been evaluated in a single Phase 1 trial, NCT06148181, titled "A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants." The trial enrolled 41 healthy volunteers in the United States and is completed.
The Phase 1 trial NCT06148181 was a randomized, double-blind, placebo-controlled study. It evaluated single ascending doses of ABBV-141 in 41 healthy adult participants, including Western and Asian volunteers, and assessed adverse events and how the drug moves through the body.